Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
New York Bariatric Group (NYBG) is a leading multi-specialty weight loss practice providing comprehensive surgical and medical obesity treatments. The group offers a wide array of minimally invasive procedures, including gastric sleeve, gastric bypass, and duodenal switch, as well as non-surgical options like intragastric balloons. NYBG integrates a multidisciplinary care model that combines surgical excellence with nutritional counseling, psychological support, and medical weight management utilizing GLP-1 receptor agonists. With over 20 clinical locations across New York, New Jersey, and Connecticut, it is one of the largest bariatric programs in the United States. In 2022, the practice partnered with Sentinel Capital Partners to support its continued growth and geographic expansion. The group is recognized as a Center of Excellence, maintaining high standards for patient safety and long-term weight loss outcomes.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on New York Bariatric Group.